Answers are grounded in this paper and cite their sources.
Glioblastoma is the most aggressive primary neuroepithelial tumor of the central nervous system, characterized by an exceptionally poor prognosis. Despite the current integrative therapeutic approach, including maximal surgical resection followed by radiotherapy and chemotherapy, the clinical outcome remains unsatisfactory with the median overall survival of patients not exceeding 15 months. A key pathogenetic factor determining therapy resistance and inevitable tumor recurrence is the presence of a population of tumor stem cells (TSCs) in its structure. In this article, the author discusses the development of a new cytoregulatory strategy for glioblastoma treatment based on proteome-personalized molecular targeting, including the suppression of β-catenin in TSCs by drugs capable of passing the blood–brain barrier. This strategy is based on the regulation of the TSC microenvironment by blocking the CXCR4/CXCL12 signaling axis and suppression of the mechanisms that recruit immunosuppressive cells (T-regulatory lymphocytes and myeloid-derived suppressor cells) to the tumor site, which facilitates the restoration of an effective antitumor immune response. The author advances the idea of creating innovative therapeutical preparations based on autologous CD45 + cells reactivated ex vivo using exogenous DNA or RNA, which transmit an inflammatory signal to the TSC microenvironment.
No takes yet. Share an insight, caveat, or question.
Oleg Pak (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: